Ellen Zane - PAREXEL International CEO
CEO
Ms. Ellen M. Zane is an Independent Director of Parexel International Corporationrationration. She is Chairman of the Compensation Committee and a member of the Human Resources Committee. Since September 2011, Ms. Zane has served as CEO Emeritus and Vice Chair, Board of Trustees of Tufts Medical Center, an academic medical center that is the principal teaching hospital for Tufts University School of Medicine in Boston, Massachusetts. From January 2004 to September 2011, she served as President and Chief Executive Officer of Tufts Medical Center. From May 1994 to January 2004, she served as Network President for Partners Healthcare System, a physician and hospital network founded by the Harvard affiliated Massachusetts General Hospital and Brigham and Womens Hospital. Prior to 2004, Ms. Zane served as Chief Executive Officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane currently serves on the boards of directors of Boston Scientific Corporationrationration, Brooks Automation, Inc., Press Ganey Holdings, Inc., Century Capital Management Inc., and Fiduciary Trust Company. since 2006.
| Age | 64 |
| Tenure | 18 years |
| Phone | 781 487-9900 |
| Web | http://www.parexel.com |
Ellen Zane Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ellen Zane against PAREXEL International stock is an integral part of due diligence when investing in PAREXEL International. Ellen Zane insider activity provides valuable insight into whether PAREXEL International is net buyers or sellers over its current business cycle. Note, PAREXEL International insiders must abide by specific rules, including filing SEC forms every time they buy or sell PAREXEL International'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ellen Zane over three months ago Acquisition by Ellen Zane of 1081 shares of Synchrony Financial subject to Rule 16b-3 | ||
Ellen Zane over three months ago Acquisition by Ellen Zane of tradable shares of Synchrony Financial subject to Rule 16b-3 | ||
Ellen Zane over six months ago Acquisition by Ellen Zane of 1350 shares of Synchrony Financial subject to Rule 16b-3 | ||
Ellen Zane over six months ago Acquisition by Ellen Zane of 1217 shares of Synchrony Financial subject to Rule 16b-3 |
PAREXEL International Management Efficiency
The company has return on total asset (ROA) of 0.0471 % which means that it generated a profit of $0.0471 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.15 %, meaning that it created $0.15 on every $100 dollars invested by stockholders. PAREXEL International's management efficiency ratios could be used to measure how well PAREXEL International manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has a current ratio of 1.42, which is within standard range for the sector. Debt can assist PAREXEL International until it has trouble settling it off, either with new capital or with free cash flow. So, PAREXEL International's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PAREXEL International sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PAREXEL to invest in growth at high rates of return. When we think about PAREXEL International's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 7 records | CEO Age | ||
| Keith Smith | Boyd Gaming | 63 | |
| Daniel Gladstone | Ainsworth Game Technology | 62 | |
| Vincent Roche | Analog Devices | 64 | |
| Lawrence Levy | Ainsworth Game Technology | N/A | |
| Duncan Hon | Emerson Radio | 58 | |
| Michael Slessor | FormFactor | 54 | |
| John Suzuki | BK Technologies | 59 | |
Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0471 |
PAREXEL International Leadership Team
Elected by the shareholders, the PAREXEL International's board of directors comprises two types of representatives: PAREXEL International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PAREXEL. The board's role is to monitor PAREXEL International's management team and ensure that shareholders' interests are well served. PAREXEL International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PAREXEL International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michelle Graham, Chief Human Resource Officer, Senior Vice President | ||
| Ulf Schneider, Chief Administrative Officer, Senior Vice President | ||
| Thomas Senderovitz, Senior Vice President - Clinical Research Services | ||
| Dana Callow, Presiding Independent Director | ||
| Emma Reeve, Interim CFO, Corporate Vice President Controller | ||
| Josef Rickenbach, Founder, Chairman and CEO | ||
| Patrick Fortune, Independent Director | ||
| Eduard Holdener, Independent Director | ||
| Simon Harford, CFO, Senior Vice President | ||
| Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access | ||
| Gadi Saarony, Senior Vice President - Clinical Research Services | ||
| Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center | ||
| Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting | ||
| Xavier Flinois, President - Perceptive Informatics | ||
| Douglas Batt, Sr. VP, General Counsel and Secretary | ||
| Sybrand Pretorius, Senior Vice President Chief Scientific Officer | ||
| Maykin Ho, Director | ||
| Richard Love, Independent Director | ||
| Ronald Aldridge, Sr. Director, Investor Relations | ||
| Mark Goldberg, President COO | ||
| Roland Andersson, Senior Vice President - Clinical Research Services | ||
| Christopher Lindop, Independent Director | ||
| Ingo Bank, CFO and Sr. VP | ||
| David Godwin, Senior Vice President-Global Business |
PAREXEL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PAREXEL International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0471 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 11.04 % | |||
| Current Valuation | 4.87 B | |||
| Shares Outstanding | 51.12 M | |||
| Shares Owned By Insiders | 2.00 % | |||
| Shares Owned By Institutions | 90.14 % | |||
| Number Of Shares Shorted | 506.64 K | |||
| Price To Earning | 42.76 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PAREXEL International using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in PAREXEL Stock
If you are still planning to invest in PAREXEL International check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PAREXEL International's history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |